Table 2. Therapy.
| Bridging without ASA (n = 181) | Bridging with ASA (n = 50) | p | |
|---|---|---|---|
| Any preexisting antiplatelets, n (%) | 62/179 (34.6) | 11 (22.0) | 0.122 |
| Aspirin, n (%) | 48/62 (77.4) | 10/11 (90.9) | |
| Clopidogrel, n (%) | 13/62 (21.0) | 0 | |
| Dual Antiplatelet therapy, n (%) | 1/62 (1.6) | 1/11 (9.1) | |
| Unclear | 2 | 0 | |
| Bridging Thrombolysis | |||
| IVT | |||
| Minutes from onset to start of IVT, mean (range) | 164 (58) | 166 (58) | 0.654 |
| rtPA dose (mg), mean (SD) | 51.5 (14.0) | 54.2 (14.1) | 0.242 |
| ET | |||
| Minutes from onset to start of ET, mean (range) | 270 (83) | 297 (102) | 0.102 |
| Mechanical thrombolysis, n (%) | 165 (91.2) | 47 (94.0) | 0.771 |
| Stenting intervention, n (%) | 8 (4.4) | 36 (72.0) | <0.001 |
| Intracranial stenting, n (%) | 3 (1.7) | 9 (18.0) | <0.001 |
| Extracranial stenting, n (%) | 5 (2.8) | 32 (64.0) | <0.001 |
| Administration of Urokinase, n (%) | 51 (28.2) | 18 (36.0) | 0.298 |
| Combined Urokinase and mechanical thrombolysis, n (%) | 35 (68.6) | 15 (83.3) | 0.358 |
| Combined Urokinase and Stenting, n (%) | 3 (5.9) | 11 (61.1) | <0.001 |
| Urokinase dose (IU), mean (SD) | 123000 (238000) | 154000 (261000) | 0.344 |
Abbreviations: ASA: Acetyl salicylic acid, IVT: intravenous thrombolysis, ET endovascular thrombectomy, SD: standard deviation